Sagimet Biosciences Reports Q3 2025 Financial Results with $12.9M Net Loss

Sagimet Biosciences Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $12.9 million, a decrease from the $14.6 million loss recorded in the same period last year. The company’s total operating expenses for the quarter were $14.3 million, down 15% from $16.9 million in the prior year, primarily due to a significant reduction in research and development costs, which fell by 23% to $9.7 million. This decrease was attributed to lower clinical trial expenses related to the Phase 3 program of its lead drug candidate, denifanstat, for metabolic dysfunction-associated steatohepatitis (MASH).

In terms of year-to-date performance, Sagimet reported a net loss of $41.5 million for the nine months ending September 30, 2025, compared to a loss of $29.4 million for the same period in 2024, marking a 41% increase. Total operating expenses for the nine-month period rose by 27% to $46.1 million, driven by a 33% increase in research and development expenses, which were largely due to costs associated with advancing clinical trials for denifanstat and the initiation of a Phase 1 trial for another drug candidate, TVB-3567.

The company’s cash and cash equivalents decreased significantly to $32.5 million as of September 30, 2025, down from $75.8 million at the end of 2024. This decline reflects the ongoing investment in clinical development and operational costs. Sagimet's total current assets also fell to $119.5 million from $152.8 million at the end of the previous fiscal year. The company has an accumulated deficit of $336.8 million, indicating the financial challenges it faces as it continues to develop its drug candidates.

Strategically, Sagimet has made notable advancements in its clinical programs. The company initiated a Phase 1 pharmacokinetic trial in September 2025 for a combination therapy involving denifanstat and resmetirom, targeting MASH. Additionally, its partner, Ascletis BioScience, reported successful results from a Phase 3 trial of denifanstat for acne in China, with plans to submit a New Drug Application to the Chinese regulatory authorities. The company also entered into a term sheet with a contract manufacturing organization, which included a $2.5 million upfront payment recognized as a research and development expense.

Looking ahead, Sagimet anticipates that its existing cash, cash equivalents, and marketable securities will be sufficient to fund operations for at least the next 12 months. However, the company acknowledges the need for additional capital to support ongoing research and development efforts and to navigate the complexities of regulatory approvals. The outlook remains cautious, with the potential for future financing activities to ensure continued progress in its clinical trials and product development initiatives.